| Jessica Knapmeyer, CRNP | |
|
104a Physicians Dr, Muscle Shoals, AL 35661-2100 | |
| (256) 383-6070 | |
| (256) 381-4022 |
| Full Name | Jessica Knapmeyer |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 104a Physicians Dr, Muscle Shoals, Alabama |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861137812 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 1-169533 (Alabama) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 1-169533 (Alabama) | Primary |
| Entity Name | Express Med Of Alabama Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215185996 PECOS PAC ID: 5496041378 Enrollment ID: O20160831002384 |
News Archive
Repligen Corporation announced today that it has filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) for a Phase 1 study of RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor. This is a double-blind, single ascending dose, Phase 1 study in healthy volunteers to evaluate the pharmacokinetic and safety profile of RG2833 in up to 40 subjects.
Antibodies developed by researchers at Rensselaer Polytechnic Institute are unusually effective at preventing the formation of toxic protein particles linked to Alzheimer's disease and Parkinson's disease, as well as Type 2 diabetes, according to a new study.
As a sugar substitute, zero-calorie sweeteners may reduce tooth decay and blood sugar spikes. Seven are approved worldwide and safe for humans - but does this mean they're healthy?
Amgen today announced the U.S. Food and Drug Administration (FDA) approved a new indication for Prolia (denosumab) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture.
› Verified 8 days ago
| Entity Name | Lister Health Care Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174579213 PECOS PAC ID: 5395646202 Enrollment ID: O20211111002469 |
News Archive
Repligen Corporation announced today that it has filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) for a Phase 1 study of RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor. This is a double-blind, single ascending dose, Phase 1 study in healthy volunteers to evaluate the pharmacokinetic and safety profile of RG2833 in up to 40 subjects.
Antibodies developed by researchers at Rensselaer Polytechnic Institute are unusually effective at preventing the formation of toxic protein particles linked to Alzheimer's disease and Parkinson's disease, as well as Type 2 diabetes, according to a new study.
As a sugar substitute, zero-calorie sweeteners may reduce tooth decay and blood sugar spikes. Seven are approved worldwide and safe for humans - but does this mean they're healthy?
Amgen today announced the U.S. Food and Drug Administration (FDA) approved a new indication for Prolia (denosumab) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jessica Knapmeyer, CRNP 970 Cox Creek Pkwy, Florence, AL 35633-1631 Ph: (256) 760-1655 | Jessica Knapmeyer, CRNP 104a Physicians Dr, Muscle Shoals, AL 35661-2100 Ph: (256) 383-6070 |
News Archive
Repligen Corporation announced today that it has filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) for a Phase 1 study of RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor. This is a double-blind, single ascending dose, Phase 1 study in healthy volunteers to evaluate the pharmacokinetic and safety profile of RG2833 in up to 40 subjects.
Antibodies developed by researchers at Rensselaer Polytechnic Institute are unusually effective at preventing the formation of toxic protein particles linked to Alzheimer's disease and Parkinson's disease, as well as Type 2 diabetes, according to a new study.
As a sugar substitute, zero-calorie sweeteners may reduce tooth decay and blood sugar spikes. Seven are approved worldwide and safe for humans - but does this mean they're healthy?
Amgen today announced the U.S. Food and Drug Administration (FDA) approved a new indication for Prolia (denosumab) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture.
› Verified 8 days ago
Kristy Miles, CRNP Nurse Practitioner Medicare: May Accept Medicare Assignments Practice Location: 108 Avalon Ave, Muscle Shoals, AL 35661 Phone: 256-389-9300 | |
Mr. Thaddeus Jason Boughton, ANP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1110 E 6th Street Suite E, Muscle Shoals, AL 35661 Phone: 256-314-2431 Fax: 256-314-2435 | |
Mrs. Melissa Anne Aycock, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 104a Physicians Dr, Muscle Shoals, AL 35661 Phone: 256-383-6070 Fax: 256-381-4022 | |
Jessica Byrd, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 716 State St, Muscle Shoals, AL 35661 Phone: 256-381-6963 Fax: 256-826-0303 | |
Laura Geneva Gilmer, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 210 Avalon Ave, Muscle Shoals, AL 35661 Phone: 256-826-1001 Fax: 256-978-5118 | |
Elizabeth Anne Raper, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2400 Avalon Ave, Suite B, Muscle Shoals, AL 35661 Phone: 256-386-0809 Fax: 256-383-8000 | |
Stacy Davis, ANCC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 503 W State St, Muscle Shoals, AL 35661 Phone: 256-978-4441 |